Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (GREY:FRTX)

Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

GlobeNewswire June 17, 2024

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

GlobeNewswire February 14, 2024

Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th

GlobeNewswire December 27, 2023

Fresh Tracks Therapeutics Announces Listing on OTC Pink Market

GlobeNewswire December 19, 2023

Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th

GlobeNewswire December 18, 2023

Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders

GlobeNewswire December 15, 2023

Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

GlobeNewswire December 1, 2023

Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders

GlobeNewswire November 17, 2023

Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2023

Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

GlobeNewswire September 19, 2023

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2023

Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

GlobeNewswire July 21, 2023

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 10, 2023

Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 30, 2023

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

GlobeNewswire March 7, 2023

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

GlobeNewswire January 27, 2023

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

GlobeNewswire January 11, 2023

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2022

Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022

GlobeNewswire November 3, 2022

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

GlobeNewswire September 13, 2022